Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a research analogue of the N-terminal fragment of adrenocorticotropic hormone (ACTH) — specifically the ACTH(4-7) region — with a Pro-Gly-Pro tripeptide appended at its C-terminus to improve stability in laboratory conditions . Because its N-terminal core overlaps structurally with alpha-melanocyte-stimulating hormone (α-MSH), research literature classifies Semax as a synthetic melanocortin derivative . It emerged primarily from Russian neuroscience and pharmacology research programs.

Q: What is the difference between Semax and ACTH?

ACTH (adrenocorticotropic hormone) is a 39-amino-acid peptide produced endogenously by the pituitary gland; its primary characterized role in the literature involves stimulating cortisol release from the adrenal cortex. Semax is a much shorter, synthetic fragment: seven amino acids corresponding to ACTH residues 4 through 7 with a Pro-Gly-Pro stabilizer. Published research has examined Semax for interactions with melanocortin-pathway receptors and neurotrophin gene expression , which differ substantially from the adrenal-stimulating function associated with full-length ACTH. The two are related by sequence but are studied in quite different research contexts.

Q: What signaling pathways has published research examined for Semax?

The published pre-clinical literature has primarily examined Semax in the context of: - Neurotrophin signaling — specifically BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), and TrkB (the primary BDNF receptor). Multiple rodent studies have reported changes in the mRNA and protein levels of these factors following Semax administration in animal models . - Melanocortin receptor interactions — given Semax's structural derivation from the ACTH/α-MSH family. The five known melanocortin receptor subtypes (MC1R–MC5R) are the framing system for this research . - Monoaminergic system markers — a rodent study examined striatal serotonergic and dopaminergic parameters following Semax administration . - Transcriptomic changes in ischemia models — genome-wide RNA-Seq studies in rodent middle cerebral artery occlusion models have characterized Semax's effects on gene-expression programs involving neurotrophin, immune, and neurotransmitter pathways . All of these represent laboratory findings in animal or cell-based models. They are not established human mechanisms.

Q: How does Semax differ from Selank?

Semax and Selank are both synthetic heptapeptides with Pro-Gly-Pro C-terminal extensions, and both emerged from Russian research programs, but they have different structural origins and different primary studied receptor systems. Semax is derived from ACTH(4-7); Selank is derived from tuftsin, an endogenous tetrapeptide associated with immune function. The Semax literature is oriented toward melanocortin-pathway and neurotrophin interactions; the Selank literature has focused more on GABAergic system interactions — with one study characterizing Selank as a concentration-dependent allosteric modulator of GABA-A receptors — and on enkephalin-degrading enzyme inhibition. Both compounds have been studied together using resting-state fMRI in healthy research participants, with investigators examining functional connectivity differences between the two conditions . For a full comparison, see the dedicated Semax vs. Selank spoke.

Q: What does the Semax literature say about BDNF?

BDNF (brain-derived neurotrophic factor) is a protein involved in neurotrophin signaling. A 2004 in-vivo rodent study reported that Semax stimulated BDNF expression across multiple rat brain regions, with measured changes at both mRNA and protein levels, and also affected TrkB (the primary BDNF receptor) expression . A subsequent study compared the temporal dynamics of BDNF and NGF gene expression across hippocampus, frontal cortex, and retina following Semax administration, finding that the direction and magnitude of expression changes were region- and time-dependent . Studies in rodent ischemia models have reported that Semax-treated animals showed differential neurotrophin gene expression compared to controls, as part of broader transcriptome-level analyses . These are animal and cell-based observations; they do not establish what Semax does to BDNF in humans.

Q: Has Semax been studied in any human research?

The human research on Semax is limited. Most of the published literature involves rodent models and in-vitro (cell-culture) assays. The published studies closest to human investigation are functional neuroimaging studies. One study examined Semax's effects on the default mode network (a resting-state brain network) using fMRI . A separate study examined both Semax and Selank using whole-brain resting-state fMRI in 52 healthy adult research participants, comparing functional connectivity patterns before and after administration . These are mechanistic neuroimaging studies in a healthy-volunteer context — not clinical trials assessing therapeutic outcomes. Semax is not an approved pharmaceutical product in most jurisdictions, and its safety and efficacy in humans has not been established through controlled clinical trials.

Q: Is Semax the same as "nootropic" compounds sold in some markets?

The popular "nootropic" label is applied to Semax based on the studied signaling systems in the pre-clinical literature (melanocortin/neurotrophin interactions, monoaminergic system effects in rodents). This label is not a validated clinical classification, and "nootropic" is not an approved category of drug effect. Responsible research framing describes Semax in terms of what laboratory studies have observed — receptor pathway associations, transcriptional changes in animal models, neuroimaging signal differences in research participants — not in terms of cognitive or neurological benefits in people. At Obsessed Living, Semax is supplied for research use only, not for human consumption.

Q: What is the source and status of the Semax research literature?

The Semax research base is substantially concentrated in Russian academic and pharmaceutical research institutions, which reflects the compound's development history. This is relevant context when evaluating the literature — the body of work, while meaningful at a pre-clinical level, has not been replicated through the kinds of independent, multi-center clinical programs that characterize pharmaceutical development in most Western regulatory systems. Recent research published in international journals (including PMC-indexed open-access studies) has begun to extend this literature, but the pre-clinical model remains the dominant frame. For more on the specific signaling pathways, see Semax, BDNF & Melanocortin Signaling. For a comparison with Selank, see Semax vs. Selank: What the Research Compares. For the full overview, see the Semax research pillar.

Research Library · Obsessed Living Research Team

Semax: Research Overview, Mechanism & Published Studies

What Semax is

Semax is a synthetic heptapeptide with the amino-acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design is derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH), specifically the ACTH(4-10) region, with a C-terminal Pro-Gly-Pro stabilizing addition [1, 2]. Because the parent ACTH sequence overlaps with that of alpha-melanocyte-stimulating hormone (α-MSH), Semax is classified in the research literature as a synthetic melanocortin derivative [1].

The compound emerged primarily from Russian neuroscience programs and has accumulated a body of pre-clinical research — predominantly in rodent and cell-culture models — that has examined its interactions with neurotrophin signaling, monoaminergic neurotransmitter systems, and gene-expression patterns in brain tissue. It should be noted that this body of work is largely pre-clinical; the compound is supplied for laboratory research use only and is not for human consumption.

Structure and classification

As a heptapeptide (seven amino acids), Semax is compact enough to cross biological barriers in research models, which has made it a common subject in studies examining central nervous system signaling pathways. Its structural relationship to both ACTH and α-MSH positions it at the intersection of two well-characterized receptor families — the melanocortin receptor system (MC1R through MC5R) and the broader adrenocorticotropin research space [1, 3].

The Pro-Gly-Pro C-terminal extension distinguishes Semax from the raw ACTH(4-10) fragment and has been the subject of separate research; published studies have examined whether this tripeptide tail contributes independently to the compound's observed effects in laboratory models [4].

Signaling pathways published research has investigated

Studies — conducted predominantly in animal and in-vitro (cell-based) models — have examined Semax in the context of several biological systems. These are descriptions of what researchers have *studied*, not statements of effect in humans:

BDNF and neurotrophin gene expression. A foundational study reported that Semax stimulated BDNF expression in multiple rat brain regions in vivo [5]. Subsequent work found that intranasal application of Semax was associated with changes in both BDNF and NGF mRNA levels across hippocampus, frontal cortex, and retina in rodent models, with the temporal dynamics of expression varying by region and time point [6]. A more recent study confirmed that both Semax and the Pro-Gly-Pro tripeptide activated the transcription of neurotrophins and their receptor genes in rat cortex following middle cerebral artery occlusion in the model system [4].
Melanocortin receptor interactions. Because Semax shares structural features with ACTH(4-10) and α-MSH, research has examined its relationship to the melanocortin receptor system. Published literature categorizes Semax as interacting with melanocortin-type pathways [1], and the five known melanocortin receptor subtypes (MC1R–MC5R) are characterized in the wider literature as mediating diverse effects in both peripheral and central tissues [3].
Monoaminergic system interactions. A 2006 rodent study investigated the effects of Semax on neurochemical parameters of the dopaminergic and serotonergic systems, reporting measurable changes in serotonergic markers (specifically 5-HIAA in striatum) following administration, while direct dopamine-metabolite concentrations were not significantly altered in that experimental model [7].
Transcriptomic changes following ischemia models. Genome-wide RNA-Seq analyses conducted in rodent middle cerebral artery occlusion models have examined how Semax affects gene-expression programs in brain tissue, with studies reporting differential expression of genes associated with immune response, neurotransmitter signaling, and neurotrophin pathways [8, 9].
Default mode network functional connectivity. Neuroimaging-level research has examined Semax in the context of resting-state functional connectivity. One study investigated its effects on the brain's default mode network [10]; a separate study examined both Semax and the related peptide Selank using whole-brain resting-state fMRI in healthy human research participants, reporting between-condition differences in functional connectivity involving the amygdala [11].

The state of the literature

The Semax research base is characterized by several important features that any rigorous discussion must acknowledge:

Pre-clinical dominance. The majority of studies have been conducted in rodent and cell-based models. These systems allow controlled examination of molecular pathways but do not establish what a compound does in humans.
Russian research program concentration. A substantial portion of Semax research has originated from Russian academic and pharmaceutical research institutions. This geographic concentration is relevant context when evaluating the literature — it reflects the compound's development history rather than a global clinical program.
"Nootropic" framing in the popular literature is not a research conclusion. Popular sources frequently attach "nootropic," "cognitive enhancer," or "focus" language to Semax. Published research examines receptor interactions, gene-expression changes, and neurochemical markers in laboratory models — it does not validate benefit claims in people. Responsible discussion stays in the research register.
Human data is limited. Semax is not an approved pharmaceutical product in most jurisdictions. The neuroimaging studies referenced above represent the category of closest approach to human investigation, but they are functional-connectivity studies in healthy research participants, not clinical trials.

This is precisely why credible discussion of Semax stays in the research register — "published studies have investigated," "in-vitro models observed," "rodent experiments reported" — rather than making claims about what the compound does for a person.

How researchers handle it

In laboratory settings, Semax is typically supplied as a lyophilized powder or research-grade solution for reconstitution and use in controlled in-vitro or in-vivo models. Material used for research should be accompanied by a Certificate of Analysis confirming sequence identity and HPLC-verified purity so that the substance under investigation is well-characterized.

Go deeper

Semax, BDNF & Melanocortin Signaling in Published Research — a closer look at the specific neurotrophin and receptor pathways the literature has examined.
Semax vs. Selank: What the Research Compares — how these two Russian-developed neuropeptides differ in their studied receptor targets and research profiles.
Semax Research FAQ — common questions about Semax, answered in a research context.
Semax Peptide Research Overview — a broader overview of the Semax literature, including background on its development history.

Research materials

Related compound: Semax — supplied as research-grade material with Certificate of Analysis. Research use only. Not for human consumption.

The Obsessed Living Research Team summarizes peer-reviewed peptide research for educational, research-use reference. Content is not medical advice. Our research standards.

Semax: Research Overview, Mechanism & Published Studies

What Semax is

Structure and classification

Signaling pathways published research has investigated

The state of the literature

How researchers handle it

Go deeper

Research materials

References

Related research

Related compounds

Compliance & Disclaimer